Cyproterone Acetate (Androcur®)

Common name: Cyproterone Acetate
Brand name: Androcur®
 

What is Cyproterone Acetate?

Cyproterone Acetate is an anti-androgen therapy used to treat advanced prostate cancer. It works by slowing or stopping the production of testosterone in the body to slow the growth of prostate cancer cells.
 

How is Cyproterone Acetate administered?

Cyproterone Acetate is administered either orally as a tablet or as an intramuscular injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received cyproterone acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Hair loss
  • Impotence
  • Increased bowel movements
  • Increased hair growth
  • Loss of energy
  • Reduced sexual interest
  • Weight gain
 

Is Cyproterone Acetate covered in my province or territory?*

Cyproterone acetate is covered by all provincial/territorial drug programs.


*Source: http://drugcoverage.ca/en-ca/search-results.aspx?ID=17912
Last Reviewed: July 2017

Help us take the first steps toward prevention. Donate Now




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Do men’s toenails contain clues about prostate cancer prevention?

Toronto, January 29, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.
More

Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.
More

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More


Click here for news archive